https://www.news-medical.net/news/2007/05/24/25569.aspx
Clinical study results on bifeprunox for schizophrenia
Jun 20, 2019 - Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult...
clinical study resultsschizophrenia
https://www.jnj.com/media-center/press-releases/updated-phase-2-captivate-study-results-demonstrate-sustained-clinical-benefit-of-fixed-duration-imbruvica-ibrutinib-plus-venetoclax-as-first-line-treatment-for-patients-with-chronic-lymphocytic-leukaemia-including-those-with-high-risk-disease
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration...
Jul 18, 2025 - At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients1